{
    "organizations": [],
    "uuid": "c54da7c5ea5e6e3994c24fadb69ac60ab1e406de",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fda-accepts-shires-biologics-licen/brief-fda-accepts-shires-biologics-license-application-idUSFWN1QD0E4",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA Accepts Shire's Biologics License Application",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 23 (Reuters) - Shire Plc:\n* FDA ACCEPTS SHIRE‘S BIOLOGICS LICENSE APPLICATION AND GRANTS PRIORITY REVIEW FOR LANADELUMAB FOR PREVENTION OF ATTACKS IN HEREDITARY ANGIOEDEMA PATIENTS​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)\n ",
    "published": "2018-02-23T15:14:00.000+02:00",
    "crawled": "2018-02-24T13:12:26.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "shire",
        "plc",
        "fda",
        "accepts",
        "shire",
        "biologics",
        "license",
        "application",
        "grant",
        "priority",
        "review",
        "lanadelumab",
        "prevention",
        "attack",
        "hereditary",
        "angioedema",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}